Response to Secukinumab Treatment in Active Psoriatic Arthritis Patients- Single Center Experience

• Published in: Ankara Ueniversitesi Tip Fakültesi mecmuasi 2021-08, Vol.74 (2), p.161-165
• Main Authors: Keleşoğlu Dinçer, Ayşe Bahar, Sezer, Serdar, Aydemir Gülöksüz, Emine Gözde, Yayla, Müçteba Enes, Torgutalp, Murat, Uslu Yurteri, Emine, Okatan, İlyas Ercan, Şahin Eroğlu, Didem, Yüksel, Mehmet Levent, Turgay, Tahsin Murat, Kınıklı, Gülay, Ateş, Aşkın
• Format: Article
• Language: eng ; tur
• Subjects: Arthritis; Cytokines; Drug therapy; Inflammation; Monoclonal antibodies; Proteins; Psoriatic arthritis
• ISSN: 1307-5608; 0365-8104; 1307-5608
• DOI: 10.4274/atfm.galenos.2021.25483

Objectives: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects peripheral joints, axial skeleton and enthesis, nail and skin. T helper-17 cells and Interleukin-17 (IL-17) play a major role in PsA pathogenesis. Secukinumab is a fully human monoclonal immunoglobulin G1 antibody that neutralizes IL-17A which is used for the treatment of moderate/severe psoriasis and PsA. In this study, we aimed to evaluate the response rates of PsA patients, who were followed up at Ankara University Faculty of Medicine, Department of Rheumatology, Policlinic of Biological Drug at the 16th week of secukinumab treatment. Materials and Methods: In this retrospective study, 18-year-old and older PsA patients, who were diagnosed according to the Classification Criteria for Psoriatic Arthritis and who were started to secukinumab treatment from May 2018 to December 2019, were enrolled. The disease activity indices at the beginning and at the 16th week of the secukinumab treatment were analyzed. A p-value of